ES2161354T3 - Compuestos mimeticos de la hoja beta y su uso como inhibidores de proteasas. - Google Patents

Compuestos mimeticos de la hoja beta y su uso como inhibidores de proteasas.

Info

Publication number
ES2161354T3
ES2161354T3 ES96910566T ES96910566T ES2161354T3 ES 2161354 T3 ES2161354 T3 ES 2161354T3 ES 96910566 T ES96910566 T ES 96910566T ES 96910566 T ES96910566 T ES 96910566T ES 2161354 T3 ES2161354 T3 ES 2161354T3
Authority
ES
Spain
Prior art keywords
beta
protease inhibitors
beta sheet
mimetic compounds
sheet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96910566T
Other languages
English (en)
Spanish (es)
Inventor
Michael Kahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecumetics Ltd
Original Assignee
Molecumetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecumetics Ltd filed Critical Molecumetics Ltd
Application granted granted Critical
Publication of ES2161354T3 publication Critical patent/ES2161354T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Materials For Medical Uses (AREA)
  • Paper (AREA)
ES96910566T 1995-03-24 1996-03-25 Compuestos mimeticos de la hoja beta y su uso como inhibidores de proteasas. Expired - Lifetime ES2161354T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41051895A 1995-03-24 1995-03-24
US54900695A 1995-10-27 1995-10-27

Publications (1)

Publication Number Publication Date
ES2161354T3 true ES2161354T3 (es) 2001-12-01

Family

ID=27021026

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96910566T Expired - Lifetime ES2161354T3 (es) 1995-03-24 1996-03-25 Compuestos mimeticos de la hoja beta y su uso como inhibidores de proteasas.

Country Status (8)

Country Link
EP (2) EP0815123B1 (enExample)
JP (4) JPH10508035A (enExample)
AT (1) ATE206433T1 (enExample)
AU (2) AU712581B2 (enExample)
CA (2) CA2215695C (enExample)
DE (1) DE69615671T2 (enExample)
ES (1) ES2161354T3 (enExample)
WO (1) WO1996030035A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840835A (en) * 1995-10-30 1998-11-24 Merck & Co., Inc. Inhibitors of peptide binding to MHC class II proteins
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
US5817757A (en) * 1995-10-30 1998-10-06 Merck & Co., Inc. Inhibitors of peptide binding to MHO class II proteins
WO1997016425A1 (en) * 1995-10-30 1997-05-09 Merck & Co., Inc. Novel inhibitors of peptide binding to mhc class ii proteins
GB9702377D0 (en) * 1996-02-23 1997-03-26 Zeneca Ltd Peptide derivatives
US6541453B2 (en) 1996-06-07 2003-04-01 Syngenta Limited Peptide derivatives
WO1997048687A1 (en) * 1996-06-18 1997-12-24 Warner-Lambert Company Process for the preparation of chiral keto-heterocycles of basic amino acids
JP2001524931A (ja) * 1996-08-05 2001-12-04 モレキュメティクス リミテッド プロテアーゼおよびキナーゼのインヒビターとしてならびに転写因子のインヒビターとしてのβシート模倣物の使用
EP1661566A3 (en) * 1996-08-05 2008-04-16 Myriad Genetics, Inc. Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors
GB9621836D0 (en) 1996-10-19 1996-12-11 Zeneca Ltd Peptide compounds
GB9624562D0 (en) 1996-11-27 1997-01-15 Zeneca Ltd Peptide derivatives
GB9625865D0 (en) * 1996-12-12 1997-01-29 Zeneca Ltd Peptides
EP1053246B1 (en) * 1998-02-12 2003-01-02 Molecumetics, Ltd. Beta-sheet mimetics and methods relating to the use thereof
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
YU61401A (sh) 1999-01-27 2005-07-19 Orto-Mcneil Pharmaceuticals Inc. U.S. Peptidil heterociklični ketoni korisni kao inhibitori triptaze
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
US6699855B2 (en) * 2000-02-29 2004-03-02 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
WO2011096440A1 (ja) 2010-02-03 2011-08-11 PRISM BioLab株式会社 天然変性タンパク質に結合する化合物およびそのスクリーニング方法
RU2728785C2 (ru) 2014-10-06 2020-07-31 Кортексим, Инк. Ингибиторы лизинспецифичного гингипаина
CA3004095A1 (en) 2015-11-09 2017-05-18 Cortexyme, Inc. Inhibitors of arginine gingipain
CN109983012B (zh) 2016-09-16 2023-12-01 莱特豪斯制药公司 赖氨酸牙龈蛋白酶的酮抑制剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA896851B (en) * 1988-09-14 1990-06-27 Hoffmann La Roche Use of ace-inhibitors

Also Published As

Publication number Publication date
AU713530B2 (en) 1999-12-02
EP0817642A1 (en) 1998-01-14
EP0815123A1 (en) 1998-01-07
CA2215695C (en) 2003-09-16
JP2000319295A (ja) 2000-11-21
AU5372996A (en) 1996-10-16
DE69615671D1 (de) 2001-11-08
ATE206433T1 (de) 2001-10-15
AU712581B2 (en) 1999-11-11
CA2215695A1 (en) 1996-10-03
DE69615671T2 (de) 2002-08-08
AU5371496A (en) 1996-10-16
WO1996030035A1 (en) 1996-10-03
JP2004131511A (ja) 2004-04-30
JPH10508034A (ja) 1998-08-04
JP4152900B2 (ja) 2008-09-17
JPH10508035A (ja) 1998-08-04
CA2215720A1 (en) 1996-10-03
EP0815123B1 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
ES2161354T3 (es) Compuestos mimeticos de la hoja beta y su uso como inhibidores de proteasas.
FI972390A0 (fi) Sytokiini nimeltä Lerk-7
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
EP1712623A3 (en) Selection of proteins using RNA-protein fusions
BG102071A (en) Minor molecule inhibitors of rotamase enzymic activity
DE59903410D1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
ATE293159T1 (de) Stabilisierendes verdünnungsmittel für polypeptide und antigene
NO965411D0 (no) N-terminalt forlengede proteiner uttrykt i gjær
DK0996409T3 (da) Præparat til at forsinke hårvækst og tilsvarende anvendelse
DE69739898D1 (de) Tests auf proteinkinasen mit fluoreszierenden proteinsubstraten
ATE368682T1 (de) Als 2f1 bezeichnetes rezeptorprotein
AU5668100A (en) Peptide conjugates for the stabilization of membrane proteins and interactions with biological membranes
AU7571998A (en) Rapid evaluation of the ratio of biological molecules
IL157047A0 (en) Methods and devices for quantitation of glycated protein
CA2529001A1 (en) Binding peptides: methods for their generation and use
ATE305612T1 (de) Reporterverbindungen und verfahren zur auffindung von hochspezifische proteaseaktivität
BR9812498A (pt) Nucleosìdeo ligante, sua preparação e seu uso
FI971580A7 (fi) Stabiloiva väliaine virtsassa olevalle aGST:lle käytettäväksi entsyymi -immunokokeessa
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe
ATE210465T1 (de) Konjugat aus einem wirkstoff und einem nicht als körperfremd angesehenen, nativen protein
DE69738945D1 (de) Rken
WO1999064861A3 (en) Method of identifying antidepressant compounds
ATE128236T1 (de) Verwendung von atelokollagen als festträger für die fixierung eines spezifischen fängers.
SE9801530D0 (sv) Method for screening
AU8296698A (en) (kds) protein kinase molecules and uses related thereto

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 815123

Country of ref document: ES